Novo Nordisk: After the clinical trial results of kidney therapy were released, European regulators gave Ozempic a positive label evaluation.Spot gold fell 1% to $2,690.81. COMEX silver futures fell 1.5% in the day to $32.47 per ounce.
CHRISTIAN MEUNIER was appointed as the chairman of NISSAN Americas.German 2-year bond yields rose by 1 basis point to 1.96%.Lian Ping: The Central Economic Work Conference released a strong financial afterburner signal to lower the RRR or cut interest rates at the end of this year or early next year. Lian Ping, chairman of the China Chief Economist Forum and president of the Guangkai Chief Industry Research Institute, said in an interview that the Central Economic Work Conference mentioned that "a moderately loose monetary policy should be implemented" and "lowering the RRR and cutting interest rates at the right time", which means that it is expected to intensify next year. Combined with the current domestic and international situation and liquidity situation, it is expected that the RRR cut and interest rate cut will land at the end of this year and early next year. Regarding "exploring and expanding the macro-prudential and financial stability functions of the central bank", Lian Ping believes that, on the one hand, the monetary policy should be reasonable and moderate, with a steady pace, so as to avoid a big deviation from market demand; On the other hand, monetary policy should explore and expand related fields and innovate constantly in maintaining financial stability. The functional connotation of the subsequent central bank is expected to be further enriched, and its coverage function may be extended to the whole financial field. "Next, whether it is the real estate market or the stock market, we need to build a long-term mechanism for financial stability." Lian Ping said. (SSE)
Spot gold hit $2,700 per ounce, down 0.65% in the day. COMEX gold futures fell more than 1.00% in the day and are now quoted at $2,729.00 per ounce.European Central Bank President Lagarde: Economic growth is losing momentum.Novo Nordisk: After the clinical trial results of kidney therapy were released, European regulators gave Ozempic a positive label evaluation.
Strategy guide
Strategy guide
Strategy guide